Literature DB >> 15729702

EWSR1 is fused to POU5F1 in a bone tumor with translocation t(6;22)(p21;q12).

Shuichi Yamaguchi1, Yukari Yamazaki, Yuichi Ishikawa, Noriyoshi Kawaguchi, Hiroyuki Mukai, Takuro Nakamura.   

Abstract

POU5F1(OCT3/4) is a sequence-specific transcription factor that is essential for keeping germ cells and embryonic stem cells in an immature and pluripotent status. In this article, we report that POU5F1 was fused to EWSR1 in a case of undifferentiated sarcoma derived from pelvic bone with chromosomal translocation t(6;22)(p21;q12). The EWSR1-POU5F1 chimera consists of exons 1-6 of EWSR1 and exons 2-5 and a part of exon 1 of POU5F1. The predicted amino acid sequence indicates that the chimera is composed of the N-terminal QSY domain of EWS that functions as a transcriptional activation domain and the C-terminal POU DNA-binding domains derived from POU5F1. The t(6;22) tumor does not belong to any known categories of bone and soft-tissue tumors (BSTs). It is suggested that EWS-POU5F1 may act as an oncogenic transcription factor and that its expression may contribute to undifferentiated and immature phenotypes of BST. Copyright 2005 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15729702     DOI: 10.1002/gcc.20171

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  25 in total

Review 1.  Molecular pathogenesis of Ewing sarcoma: new therapeutic and transcriptional targets.

Authors:  Stephen L Lessnick; Marc Ladanyi
Journal:  Annu Rev Pathol       Date:  2011-09-19       Impact factor: 23.472

Review 2.  Advances in sarcoma genomics and new therapeutic targets.

Authors:  Barry S Taylor; Jordi Barretina; Robert G Maki; Cristina R Antonescu; Samuel Singer; Marc Ladanyi
Journal:  Nat Rev Cancer       Date:  2011-07-14       Impact factor: 60.716

Review 3.  Pituitary gland development and disease: from stem cell to hormone production.

Authors:  Shannon W Davis; Buffy S Ellsworth; María Inés Peréz Millan; Peter Gergics; Vanessa Schade; Nastaran Foyouzi; Michelle L Brinkmeier; Amanda H Mortensen; Sally A Camper
Journal:  Curr Top Dev Biol       Date:  2013       Impact factor: 4.897

Review 4.  Promiscuous partnerships in Ewing's sarcoma.

Authors:  Savita Sankar; Stephen L Lessnick
Journal:  Cancer Genet       Date:  2011-07

Review 5.  Ewing sarcoma/peripheral primitive neuroectodermal tumor and related tumors.

Authors:  Maria Tsokos; Rita D Alaggio; Louis P Dehner; Paul S Dickman
Journal:  Pediatr Dev Pathol       Date:  2012

6.  Rhabdoid Variant of Myoepithelial Carcinoma, with EWSR1 Rearrangement: Expanding the Spectrum of EWSR1-Rearranged Myoepithelial Tumors.

Authors:  Khin Thway; Nick Bown; Aisha Miah; Rob Turner; Cyril Fisher
Journal:  Head Neck Pathol       Date:  2014-07-04

Review 7.  Bone- and cartilage-forming tumors and ewing sarcoma: an update with a gnathic emphasis.

Authors:  Brian D Stewart; John D Reith; Jacquelyn A Knapik; Angela C Chi
Journal:  Head Neck Pathol       Date:  2014-11-20

8.  EWSR1-POU5F1 fusion in soft tissue myoepithelial tumors. A molecular analysis of sixty-six cases, including soft tissue, bone, and visceral lesions, showing common involvement of the EWSR1 gene.

Authors:  Cristina R Antonescu; Lei Zhang; Ning-En Chang; Bruce R Pawel; William Travis; Nora Katabi; Morris Edelman; Andrew E Rosenberg; G Petur Nielsen; Paola Dal Cin; Christopher D M Fletcher
Journal:  Genes Chromosomes Cancer       Date:  2010-12       Impact factor: 5.006

9.  Oct4 expression is not required for mouse somatic stem cell self-renewal.

Authors:  Christopher J Lengner; Fernando D Camargo; Konrad Hochedlinger; G Grant Welstead; Samir Zaidi; Sumita Gokhale; Hans R Scholer; Alexey Tomilin; Rudolf Jaenisch
Journal:  Cell Stem Cell       Date:  2007-10-11       Impact factor: 24.633

10.  EWS-Oct-4B, an alternative EWS-Oct-4 fusion gene, is a potent oncogene linked to human epithelial tumours.

Authors:  S Kim; B Lim; J Kim
Journal:  Br J Cancer       Date:  2010-01-05       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.